| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 1075 | 2018 |
| ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis X Montalban, R Gold, AJ Thompson, S Otero-Romero, MP Amato, ... Multiple Sclerosis Journal 24 (2), 96-120, 2018 | 1027 | 2018 |
| Ofatumumab versus teriflunomide in multiple sclerosis SL Hauser, A Bar-Or, JA Cohen, G Comi, J Correale, PK Coyle, AH Cross, ... New England Journal of Medicine 383 (6), 546-557, 2020 | 635 | 2020 |
| Leitlinien für Diagnostik und Therapie in der Neurologie HC Diener, C Weimar, P Berlit, G Deuschl, C Elger, R Gold, W Hacke, ... Thieme Verlag, 2012 | 557 | 2012 |
| Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis S Wintterle, B Schreiner, M Mitsdoerffer, D Schneider, L Chen, ... Cancer research 63 (21), 7462-7467, 2003 | 520 | 2003 |
| Acute disseminated encephalomyelitis: an update T Menge, B Hemmer, S Nessler, H Wiendl, O Neuhaus, HP Hartung, ... Archives of neurology 62 (11), 1673-1680, 2005 | 499 | 2005 |
| Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro C Blank, J Kuball, S Voelkl, H Wiendl, B Becker, B Walter, O Majdic, ... International journal of cancer 119 (2), 317-327, 2006 | 446 | 2006 |
| Teriflunomide and its mechanism of action in multiple sclerosis A Bar-Or, A Pachner, F Menguy-Vacheron, J Kaplan, H Wiendl Drugs 74, 659-674, 2014 | 429 | 2014 |
| A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape H Wiendl, M Mitsdoerffer, V Hofmeister, J Wischhusen, A Bornemann, ... The Journal of Immunology 168 (9), 4772-4780, 2002 | 425 | 2002 |
| Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis CG Bien, J Bauer, TL Deckwerth, H Wiendl, M Deckert, OD Wiestler, ... Annals of Neurology: Official Journal of the American Neurological …, 2002 | 422 | 2002 |
| Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation C Kleinschnitz, N Schwab, P Kraft, I Hagedorn, A Dreykluft, T Schwarz, ... Blood, The Journal of the American Society of Hematology 115 (18), 3835-3842, 2010 | 409 | 2010 |
| Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature C Kleinschnitz, P Kraft, A Dreykluft, I Hagedorn, K Göbel, MK Schuhmann, ... Blood, The Journal of the American Society of Hematology 121 (4), 679-691, 2013 | 403 | 2013 |
| Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study P Benkert, S Meier, S Schaedelin, A Manouchehrinia, Ö Yaldizli, ... The Lancet Neurology 21 (3), 246-257, 2022 | 399 | 2022 |
| Clinical relevance of brain volume measures in multiple sclerosis N De Stefano, L Airas, N Grigoriadis, HP Mattle, J O’Riordan, ... CNS drugs 28, 147-156, 2014 | 389 | 2014 |
| Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells O Neuhaus, C Farina, A Yassouridis, H Wiendl, F Then Bergh, T Dose, ... Proceedings of the National Academy of Sciences 97 (13), 7452-7457, 2000 | 378 | 2000 |
| Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in … B Schreiner, M Mitsdoerffer, BC Kieseier, L Chen, HP Hartung, M Weller, ... Journal of neuroimmunology 155 (1-2), 172-182, 2004 | 363 | 2004 |
| Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis D Schafflick, CA Xu, M Hartlehnert, M Cole, A Schulte-Mecklenbeck, ... Nature communications 11 (1), 247, 2020 | 339 | 2020 |
| How patients with multiple sclerosis acquire disability FD Lublin, DA Häring, H Ganjgahi, A Ocampo, F Hatami, J Čuklina, ... Brain 145 (9), 3147-3161, 2022 | 330 | 2022 |
| Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society N Melzer, T Ruck, P Fuhr, R Gold, R Hohlfeld, A Marx, A Melms, ... Journal of neurology 263, 1473-1494, 2016 | 317 | 2016 |
| The role of regulatory T cells in multiple sclerosis AL Zozulya, H Wiendl Nature clinical practice Neurology 4 (7), 384-398, 2008 | 316 | 2008 |
Ludwig KapposUniversity of Basel and Research Center of Clinical Neuroimmunology and Neuroscience Basel (RC2NB)Email verificata su uhbs.ch